KAMIYA BIOMEDICAL COMPANY
   25 Years!
Products  
 Search All Products
 
 
 Antibodies
 - A B C D E F G H I J K
 - L M N O P Q R S T U
 - V W X Y Z  Other
 Biochemicals
 - A B C D E F G H I J K
 - L M N O P Q R S T U
 - V W X Y Z  Other
 
 Assay Kits
 
 
 Research Interests 
 - Cancer
 - Cardiac
 
 Antibody Applications 
 - ELISA
 

Cat. No. KAI-043/KAI-050

Fructosamine

For In-Vitro Diagnostic Use

KIT COMPOSITION
Reagent 1 (R-1) 
Reagent 2 (R-2) 

PERFORMANCE

Sensitivity

An investigation of the absorbance change per minute for ten replicates of two samples, with known concentrations of fructosamine, indicated that an absorbance change per minute of 0.042 was aproximately equivalent to 1 mmol/L fructosamine.

Precision
Precision studies were performed following a modification of the procedure contained in NCCLS document EP5-T2.

Within Day (n=20) :
Mean S.D. C.V. %
  1.97
  5.57
  0.04
  0.10
  2.0
  1.8

Day to Day (n=20) :

Mean S.D. C.V. %
  1.91
  5.72
  0.06
  0.14
  3.1
  2.4
Correlation
Results obtained with this reagent (y) in 45 samples ranging in fructosamine from 1.17 - 5.94 mmol/L, were compared with those obtained in the same samples using a reagent (x) based on the same methodology. The correlation coefficient was 0.988 and the regression equation was:
y = 0.88x + 0.28 (Std Err of Y Est = 0.19)

Assay Range
1.0 - 10.0 mmol/L

INTERFERENCE

All interference studies were performed according to the procedures recommended in NCCLS guideline No. EP7-P for interference testing in clinical chemistry.

Bilirubin Up to 20 mg/dL has been demonstrated to have a negligible effect (<5%)
 
Hemoglobin Up to 200 mg/dL has been demonstrated to have a negligible effect (<5%)
 
Glucose Up to 600 mg/dL has been demonstrated to have a negligible effect (<5%)
⇐   BACK
12779 Gateway Drive, Seattle, WA 98168, USA  Tel: (206) 575-8068  Fax: (206) 575-8094  E-mail: webmaster@kamiyabiomedical.com